About Avalyn Pharma
Avalyn Pharma is a private company based in Seattle, Washington. It has reported $245,069,287 raised in four offerings on Form D since November 2012. Its chief executive is Lyn Baranowski.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 22, 2023 | Oct 10, 2023 | $189,182,622fully sold | 26 | $7.2M | EquityRule 506(b) | Form D ↗ |
| Apr 24, 2020 | May 8, 2020 | $35,499,998of $35.6M target | 8 | $4.4M | EquityRule 506(b) | Form D ↗ |
| Mar 13, 2017 | Mar 24, 2017amended May 24, 2017 | $18,207,187of $64.9M target | 46 | $395K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Oct 23, 2011 | Nov 16, 2012amended Aug 12, 2015 | $2,179,480fully sold | 41 | $53,158 | Equity, Debt, OptionsRule 506(b) | Form D/A ↗2 earlier filings |
| Total, four offerings | $245,069,287 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Avalyn Pharma's Form D filed Oct 10, 2023.
Earlier filings also listed Sofia Ioannidou (director, last listed May 2020), Robert Mittendorff (director, last listed May 2020), Heather Preston (director, last listed May 2020), A. Montgomery (executive officer and director, last listed May 2020), Naveed Siddiqi (director, last listed May 2017), Mark Surber, Ph.D. (secretary, last listed May 2017), Jonathan Leff, M.D. (director, last listed May 2017) and Bruce Montgomery, M.D. (executive officer and director, last listed May 2017).